BR112022015994A2 - MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS - Google Patents

MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS

Info

Publication number
BR112022015994A2
BR112022015994A2 BR112022015994A BR112022015994A BR112022015994A2 BR 112022015994 A2 BR112022015994 A2 BR 112022015994A2 BR 112022015994 A BR112022015994 A BR 112022015994A BR 112022015994 A BR112022015994 A BR 112022015994A BR 112022015994 A2 BR112022015994 A2 BR 112022015994A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
immunizing
multivalent immunogenic
dirophilariosis
inducing
Prior art date
Application number
BR112022015994A
Other languages
Portuguese (pt)
Inventor
Kalyanasundaram Ramaswamy
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/790,277 external-priority patent/US11370814B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112022015994A2 publication Critical patent/BR112022015994A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

COMPOSIÇÃO IMUNOGÊNICA MULTIVALENTE, VETOR RECOMBINANTE, CÉLULA HOSPEDEIRA RECOMBINANTE, E, MÉTODOS PARA INDUZIR UMA RESPOSTA IMUNE PROTETORA E PARA IMUNIZAR UM ANIMAL CONTRA DIROFILARIOSE. A presente invenção é uma composição imunogênica multivalente para imunizar um animal contra filariose. Em algumas modalidades, os antígenos da composição imunogênica multivalente são baseados em proteína, baseados em DNA ou uma combinação dos mesmos. Esta invenção também provê um método e kit para detectar um nematódeo filarial e determinar a eficácia da vacina.MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS. The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

BR112022015994A 2020-02-13 2021-02-12 MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS BR112022015994A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/790,277 US11370814B2 (en) 2010-11-15 2020-02-13 Vaccine and methods for detecting and preventing filariasis
PCT/US2021/017813 WO2021163448A2 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis

Publications (1)

Publication Number Publication Date
BR112022015994A2 true BR112022015994A2 (en) 2022-10-11

Family

ID=77295222

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015994A BR112022015994A2 (en) 2020-02-13 2021-02-12 MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS

Country Status (7)

Country Link
EP (1) EP4103225A2 (en)
JP (1) JP2023513607A (en)
CN (1) CN115209916A (en)
AU (1) AU2021218797A1 (en)
BR (1) BR112022015994A2 (en)
CA (1) CA3167346A1 (en)
WO (1) WO2021163448A2 (en)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5207987A (en) 1990-05-21 1993-05-04 Pb Diagnostic Systems Inc. Temperature controlled chamber for diagnostic analyzer
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5639876A (en) * 1991-02-12 1997-06-17 Heska Corporation Nucleic acid molecules encoding novel parasitic helminth proteins
EP0648338A1 (en) 1992-07-01 1995-04-19 Behring Diagnostics Inc. Automated analytical instrument having a fluid sample holding tray transport assembly
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6063338A (en) 1997-06-02 2000-05-16 Aurora Biosciences Corporation Low background multi-well plates and platforms for spectroscopic measurements
US6229603B1 (en) 1997-06-02 2001-05-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for spectroscopic measurements
US5910287A (en) 1997-06-03 1999-06-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for fluorescence measurements of biological and biochemical samples
US6426050B1 (en) 1997-05-16 2002-07-30 Aurora Biosciences Corporation Multi-well platforms, caddies, lids and combinations thereof
US6150135A (en) * 1997-05-23 2000-11-21 Heska Corporation Dirofilaria and brugia thioredoxin peroxidase type-2 (TPX-2) nucleic acid molecules, and uses thereof
US6448089B1 (en) 1999-10-12 2002-09-10 Aurora Biosciences Corporation Multiwell scanner and scanning method
US6814933B2 (en) 2000-09-19 2004-11-09 Aurora Biosciences Corporation Multiwell scanner and scanning method
US7459314B2 (en) 2003-02-13 2008-12-02 Inverness Medical Switzerland Gmbh Lateral flow immunoassay controls
US8003407B2 (en) 2004-07-29 2011-08-23 Relia Diagnostic Systems, Llc Lateral flow system and assay
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US7387890B2 (en) 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
US7939342B2 (en) 2005-03-30 2011-05-10 Kimberly-Clark Worldwide, Inc. Diagnostic test kits employing an internal calibration system
US7976795B2 (en) 2006-01-19 2011-07-12 Rheonix, Inc. Microfluidic systems
US20100129935A1 (en) 2008-11-25 2010-05-27 Sarah Daniel Maddison Pregnancy testing method
US20100196200A1 (en) 2009-02-05 2010-08-05 Jin Po Lee Biological test strip
CN110051832B (en) * 2019-05-31 2020-11-10 四川农业大学 Heartworm disease vaccine

Also Published As

Publication number Publication date
WO2021163448A3 (en) 2021-11-25
CA3167346A1 (en) 2021-08-19
WO2021163448A2 (en) 2021-08-19
CN115209916A (en) 2022-10-18
JP2023513607A (en) 2023-03-31
AU2021218797A1 (en) 2022-08-25
EP4103225A2 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112022014808A2 (en) COMPOSITIONS AND METHODS FOR VACCINES TO PREVENT AND TREAT CORONAVIRUS-SARS-COV-2 INFECTION
CL2021000636A1 (en) African swine fever virus vaccine
BRPI0909123B8 (en) monoclonal antibodies, expression vector, host cell, pharmaceutical composition, use of said antibody, diagnostic kit and assay methods to detect the presence of influenza a virus epitopes
BR112018001572A2 (en) method for inducing an immune response, antigen, adenovirus, use of antigen and adenovirus, and polynucleotide.
ECSP17045428A (en) NEW TILAPIA VIRUSES AND THEIR USES
BRPI0518146A (en) parts kit, use of a recombinant defective adenovirus in replication, and method of vaccinating a mammal for malaria infection
BR112018017307A2 (en) isolated nucleic acid molecule, composition, and methods for inducing an immune response against a Zika virus, for treating an individual, and for preventing a Zika virus infection
BR112015002131A8 (en) RECOMBINANT VACCINIA ANKARA VIRUS (MVA), PHARMACEUTICAL COMPOSITION AND USE OF SUCH RECOMBINANT MVA
EA201990718A1 (en) VECTORS OF Adenovirus of dogs
BRPI0906997A2 (en) Protein, use of the combining protein or fragment thereof, method for inducing an immune response in an individual, method for treating a pacemaker, nicleic acid construction, host cell ezpression vector, vaccine, antibody, and, pharmaceutical composition
BR112023005961A2 (en) MODIFIED NUCLEIC ACID MOLECULE, COMBINED VACCINE, NANOPARTICLE, MRNA NANOCLUSTER, METHOD FOR PREVENTING OR TREATING A CORONAVIRUS INFECTION, METHOD FOR BOOSTING AN ADAPTIVE IMMUNE RESPONSE, IMMUNOGENIC PEPTIDE AND IMMUNOGENIC COMPOSITION
BR112022013236A2 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
BR112021026439A2 (en) African swine fever vaccine
BR112012031211A2 (en) methods and vaccine to reduce campylobacter infection
BRPI1007721B1 (en) vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66
BR112015013004A2 (en) isolated nucleic acid molecule, composition, vaccine, methods of treating an individual and preventing a tumor, protein, and peptide
BR112018008840A2 (en) single domain antibodies directed against intracellular antigens
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
BR112017002577A2 (en) recombinant vaccine, mother seed of a recombinant avian adenovirus virus and use of an avian adenovirus vector
BR112022015994A2 (en) MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS
BR112022011885A2 (en) NUCLEIC ACID MOLECULE, IMMUNOGENIC COMPOSITION, PEPTIDE, AND, METHODS TO INDUCE AN IMMUNE RESPONSE AND TO TREAT OR PREVENT A PATHOLOGY
BR112018072719A2 (en) isolated nucleic acid molecule, composition, and methods for inducing an immune response against filovirus and ebolavirus, treating an individual who has been diagnosed with ebolavirus, and preventing ebolavirus infection
BR112023015467A2 (en) MODIFIED RECOMBINANT VACCINIA ANKARA VIRAL VECTOR, METHODS FOR INCREASING AN IMMUNE RESPONSE TO A TARGET ANTIGEN IN A PATIENT AND FOR PREVENTING, TREATING OR INDUCING AN IMMUNE RESPONSE AGAINST A TARGET ANTIGEN, AND, PHARMACEUTICAL COMPOSITION
BR112017027804A2 (en) chimeric polypeptide, viral vector, composition of a babesiosis vaccine, methods of immunizing mammals against babesiosis, detection method for babesiosis infected mammals and kit for detection of babesias parasite infections in mammals
BR112018072592A2 (en) yeast vaccine vector that includes immunostimulating and antigenic polypeptides, and methods of using them